In timely news just weeks before Halloween, a clinical research group said it is enrolling patients in a clinical trial to investigate the impact of a vampire bat protein for patients who experienced an acute ischemic stroke.
The plasminogen activator, which is derived from the saliva of vampire bats, belongs to a substance class that supports the breakdown of blood clots, according to the NeuroStudies clinical research group. The only FDA-approved treatment for acute ischemic stroke must be administered within three hours of the onset of the symptoms. If approved, the thrombolytic agent could extend the treatment window to nine hours.
It seems this isn't the first clinical trial for the plasminogen activator in the treatment of acute ischemic stroke. Lundbeck, the Copenhagen-based pharmaceutical company, owns the rights to the drug it calls desmoteplase.
Desmoteplase isn't the name used for the bat protein. Another study quite aptly named the drug Draculin.